drugset / Trial / NCT01234038
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to examine the overall survival of patients with Stage IV non-small cell lung cancer (NSCLC) treated with ISIS EIF4E Rx in combination with carboplatin and paclitaxel.
Timeline
- Start
- 2010-11
- Primary completion
- 2012-10
- Completion
- 2013-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ISIS EIF4E Rx | Unknown | 800 mg | Intravenous |
| Subject | ISIS EIF4E Rx | Unknown | 1000 mg | Intravenous |
| Background | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Background | Paclitaxel | Small molecule | 200 mg/m2 | Intravenous |